Hepatitis C virus (HCV) interacts extensively with host factors to not only establish productive infection but also trigger unique pathological processes. Our recent genome-wide siRNA screen demonstrated that IkB kinase-a (IKK-a) is a crucial host factor for HCV. Here we describe a new nuclear factor kB (NF-kB)-independent and kinase-mediated nuclear function of IKK-a in HCV assembly. HCV, through its 3′ untranslated region, interacts with DEAD box polypeptide 3, X-linked (DDX3X) to activate IKK-a, which translocates to the nucleus and induces a CBP/p300-mediated transcriptional program involving sterol regulatory elementbinding proteins (SREBPs). This innate pathway induces lipogenic genes and enhances core-associated lipid droplet formation to facilitate viral assembly. Chemical inhibitors of IKK-a suppress HCV infection and IKK-a-induced lipogenesis, offering a proof-ofconcept approach for new HCV therapeutic development. Our results show that HCV uses a novel mechanism to exploit intrinsic innate responses and hijack lipid metabolism, which may contribute to high chronicity rates and the pathological hallmark of steatosis in HCV infection. npg
HCV infection is a leading cause of chronic liver disease associated with substantial morbidity and mortality worldwide 1 . A protective HCV vaccine is not available, and the current therapeutic regimen is suboptimal 2 . The virus has a unique propensity to cause persistent infection and induce progressive liver damage 3 . HCV extensively exploits host factors, such as cellular lipid metabolic pathways, for efficient propagation 4, 5 . HCV has been shown to alter the lipid metabolism of infected hepatocytes 6 , resulting in a unique pathological feature of HCV infection: hepatic steatosis. Activation of SREBPs, which are crucial transcriptional regulators of cholesterol and fatty acid metabolism 7 , has been shown in HCV-infected hepatocytes 8, 9 . However, the mechanistic basis of their activation remains unclear.
HCV activates host innate immunity that functions to limit viral infection. Recognition of viral pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs), such as RIG-I-like receptors (RLRs), and activation of various signaling pathways, including interferon regulatory factor 3 (IRF3) and NF-κB, are early steps of an intrinsic innate immune response that leads to the subsequent induction of interferons 10 . The NF-κB pathway is tightly regulated by the IKK complex, which consists of two catalytic subunits, IKK-α and IKK-β, and a regulatory subunit, NEMO (also known as IKK-γ) 11 . Activation of IKK-β and NEMO and subsequent IκB degradation are crucial steps in the activation of the canonical NF-κB pathway 12 . IKK-α preferentially phosphorylates NF-κB2 rather than IκB and leads to the activation of p52-RelB heterodimers that regulate a distinct subset of NF-κB target genes 12 . This alternative action is referred to as the noncanonical pathway 13 . IKK-α is a remarkably versatile molecule that is involved in diverse signaling pathways to regulate gene expression; many of its actions are independent of NF-κB 12, 14 . Unlike IKK-β, IKK-α can shuttle between the cytoplasm and the nucleus 15, 16 . In the nucleus, IKK-α interacts with CREB binding protein (CBP) and contributes to NF-κBmediated gene expression through phosphorylation of histone H3 (refs. 15,17,18) . The transcriptional targets of IKK-α, however, remain largely unknown.
We recently performed a genome-wide RNAi screen to discover HCV host dependencies. We identified IKK-α (under the name CHUK) 19 as being important for the HCV life cycle. Here we confirm that IKK-α is requisite for productive HCV infection and show that it upregulates lipogenesis of host cells for efficient viral assembly through transcriptional induction of SREBPs. HCV infection, through the action of the 3′ untranslated region (3′ UTR), interacts with DDX3X to activate IKK-α and thereby induces lipid droplet biogenesis. We provide a direct functional link between HCV infection, inflammation, innate immunity and hepatic lipid metabolism.
RESULTS

IKK-a is required for productive HCV infection
We previously used a two-part viral infection protocol to characterize host dependencies associated with both the early (part-one) and late (part-two) stages of the HCV life cycle 19 . We confirmed that the effect of IKK-α silencing was more pronounced in the part-two (>85% inhibition) than the part-one assay (~60% inhibition) in Huh7.5.1 cells, suggesting that IKK-α acts more during the late stage of viral infection ( Fig. 1a and Supplementary Fig. 1a) . We confirmed the effect of IKK-α depletion 19 by testing four individual siRNAs of the SMARTpool ( Fig. 1b and Supplementary Fig. 1b ). Expression of a siRNA-resistant IKK-α mutant restored HCV infection in cells treated with siRNA targeting IKK-α ( Supplementary Fig. 1c ), further validating the phenotype-specific role of IKK-α in HCV infection. IKK-α siRNA substantially impaired the production and secretion of infectious HCV by more than 90% ( Fig. 1c) . Overexpression of IKK-α by transfecting Huh7.5.1 cells with a plasmid encoding hemagglutinin-tagged IKK-α (HA-IKK-α) substantially increased infectious HCV production ( Fig. 1d) . The function of IKK-α requires its kinase activity, and the kinase-defective K44M mutant of IKK-α (called here IKK-α KM ) behaves as a dominantnegative mutant 20 . Transfection of the IKKα KM blocked HCV propagation similarly to IKK-α siRNA ( Fig. 1e) .
To further investigate the role of IKK-α in HCV infection, we tested various IKK inhibitors in HCV-infected Huh7.5.1 cells and primary human hepatocytes (PHHs) ( Fig. 1f-i and Supplementary Fig. 2) . Treatment of Huh7.5.1 cells with wedelolactone and IKK Inhibitor XII, which are chemical inhibitors of both IKK-α and IKK-β, markedly reduced HCV core protein staining and infectious viral particle production ( Fig. 1f,g) . Increasing concentrations of both compounds led to a dose-dependent decline in HCV RNA production and secretion in both Huh7.5.1 cells and PHHs that could not be accounted for by a minor cytotoxicity at high concentrations (Fig. 1h,i and Supplementary  Fig. 2b,c) . BMS-345541, an IKK-β-specific inhibitor, had little effect on HCV production ( Fig. 1f-i and Supplementary Fig. 2b,c) .
The role of IKK-a in HCV assembly and lipid droplet formation
To investigate the step of the HCV life cycle in which IKK-α is required, we used multiple virologic assays. IKK-α silencing preferentially affected extracellular HCV RNA levels in the HCV cell culture infection system (Fig. 1b) . We therefore specifically examined single-cycle replication by transfecting genomic HCV RNA into CD81-deficient Huh7 (Huh7.25) cells 21 and found that HCV replication was not affected by IKK-α silencing ( Fig. 2a) . IKK-α silencing had no effect on assays targeting individual steps of the early HCV life cycle, including entry (HCV pseudovirus assay), translation (HCV internal ribosome entry site (IRES)-driven reporter) and replication (subgenomic replicon) ( Fig. 2b and Supplementary Fig. 3 ), consistent with a predominant role of IKK-α in the late stage of the viral life cycle.
We thus hypothesized that IKK-α is involved in the assembly or secretion of infectious viral particles. The lipid droplet has been shown to play a crucial part in HCV assembly [22] [23] [24] . Consistent with this, we observed HCV proteins, particularly the core and NS5A proteins, in close proximity to lipid droplets in HCV-infected cells ( Fig. 2c and Supplementary  Fig. 4a,b ). Cells infected with HCV had a marked increase in lipid droplet numbers, lipid droplet-positive area, lipid droplet fluorescence intensity and triglyceride content, and IKK-α silencing significantly blocked this increase ( Fig. 2c and Supplementary Fig. 4b,c) . In HCV-infected cells treated with IKK-α siRNA, core protein staining was only modestly reduced, but the association between core protein and lipid droplets was diminished substantially ( Fig. 2c and Supplementary Fig. 4b ), suggesting that IKK-α is important for the association of lipid droplets with HCV proteins during the assembly process. The IKK inhibitors wedelolactone and Inhibitor XII, but not BMS-345541, showed strong inhibition of lipid droplet formation and colocalization of core protein and lipid droplets ( Supplementary Fig. 4d ). IKK-α overexpression also significantly increased the number, size and fluorescence intensity of lipid droplets ( Fig. 2d) . Conversely, transfection of the HA-IKK-α KM strongly reduced lipid droplet formation ( Fig. 2d ). Collectively these data indicate that IKK-α predominantly affects HCV-induced lipid droplet formation and viral assembly, although an additional effect on virion secretion cannot be ruled out completely.
HCV 3′ UTR activates IKK-a and lipid droplet formation
To define the mechanism of the HCV-responsive activation of IKK-α and induction of lipogenesis, we examined the role of the 3′ UTR of the viral genome, which contains a previously identified HCV PAMP molecule: a poly(U/C) sequence 25 . Transfection of HCV 3′ UTR RNA demonstrated a strong induction of lipid droplet formation, and IKK-α silencing by siRNA markedly diminished the HCV 3′ UTR-mediated increase in lipid droplet content ( Fig. 2e and Supplementary Fig. 5a ). Poly(I:C), a synthetic PAMP, also enhanced lipid droplet formation ( Supplementary Fig. 5a ).
Transfection of HA-IKK-α plasmid and HCV 3′ UTR RNA together resulted in increased amounts of phosphorylated IKK-α, whereas we did not detect IKK-α phosphorylation in cells transfected with the HA-IKK-α KM (Supplementary Fig. 5b ). Therefore HCV infection induces lipid droplet biogenesis through viral RNA-triggered activation of an IKK-α-dependent pathway.
The function of IKK-a in HCV infection is NF-kB independent IKK-α is a component of IKK that controls NF-κB activation, but it has also been implicated in NF-κB-independent functions 12 . To dissect the function of the NF-κB pathway in connection with IKK-α in HCV infection, we first silenced four major factors of the NF-κB family (NF-κB1, NF-κB2, RELA and RELB) and two IKK catalytic units essential for NF-κB activation (IKK-β and NEMO) 11 (Fig. 3a-c) . We observed an increase in HCV infection and replication ( Fig. 3a,b) , which directly contrasts the result of IKK-α silencing. Silencing of the above-mentioned NF-κB genes did not affect IKK-α-mediated induction of lipid droplet formation or enhancement of HCV propagation ( Fig. 3d,e ). In addition, signals known to activate the NF-κB pathway, such as interleukin-1β (IL-1β) and lymphotoxin-α and -β (LT-α/β), did not induce lipid droplet formation ( Fig. 3f and Supplementary  Fig. 5c ). siRNA against LT-β (also called LTB) or its receptor (LTBR), which are known to be involved in noncanonical activation of NF-κB through IKK-α 12 , had little or no effect on HCV replication or lipid droplet induction ( Supplementary Fig. 5d-g) . Further evidence for the NF-κB-independent effect of IKK-α is shown in the Supplementary Results. In addition, several previously reported NF-κB-independent functions of IKK-α are not involved in modulating HCV infection (Supplementary Results).
The role of DDX3X in HCV assembly and lipid droplet formation
We next explored the signaling pathway that mediates the specific effect of the HCV 3′ UTR on IKK-α activation. RIG-I has been shown to be the key PRR for the HCV PAMP that resides in the 3′ UTR 25 . Because RIG-I is nonfunctional in Huh7.5.1 cells 25 , we tested the roles of two other RLRs (MDA5 (also known as IFH1) and LGP2 npg (also known as DHX58)), the RLR signaling-adaptor molecule MAVS and a major downstream cytosolic kinase, TBK1. Depletion of these factors by siRNA had little or no effect on HCV-triggered or HCV 3′ UTR-triggered lipid droplet formation (Supplementary Fig. 6a-c) .
The effects on HCV replication were somewhat variable, with MDA5 siRNA causing a minor increase and LGP2 siRNA causing a modest decrease ( Supplementary Fig. 6d ), which we attribute to a positive role of MDA5 and a negative role of LGP2 in RLR signaling 26 . We then investigated whether DDX1, a putative PRR that is capable of sensing double-stranded RNA 27 , is involved in HCV 3′ UTR-mediated effects, and showed that DDX1 siRNA had no effect ( Supplementary  Fig. 6a-c) . DDX3X, another DExD/H helicase, has recently been implicated in innate immunity 28, 29 and has been shown to be important for HCV infection 30, 31 . DDX3X was also identified as a strong proviral factor in our genome-wide siRNA screen, and similar to IKK-α, its silencing had a greater effect on the late stage of the viral life cycle 19 . Silencing of DDX3X led to a more substantial inhibition of extracellular than of intracellular HCV RNA levels and a significant impairment of viral infectivity (Fig. 4a) , whereas overexpression of DDX3X increased the extracellular level of HCV RNA more than the intracellular level (Fig. 4b) . Depletion of DDX3X also abrogated the induction of lipid droplet biogenesis mediated by the HCV 3′ UTR and reduced the core-lipid droplet association in the context of HCV infection (Supplementary Fig. 6a-c) .
DDX3X interacts with HCV 3′ UTR and activates IKK-a
In HCV 3′ UTR-treated or HCV-infected cells, DDX3X redistributed to form speckle-like cytoplasmic structures (Fig. 4c,d and Supplementary  Figs. 7 and 8a) , although its overall expression remained unaltered (Supplementary Fig. 8b,c) . DDX3X colocalized specifically with transfected Cy3-labeled HCV 3′ UTR RNA but not control RNA ( Fig. 4c  and Supplementary Fig. 7) . HCV 3′ UTR RNA, but not control RNA, formed a complex with DDX3X in cell lysates (Fig. 4e) . Treatment with the HCV 3′ UTR or HCV infection induced the formation of IKK-α aggregates, which colocalized extensively with DDX3X-HCV 3′ UTR complexes (Fig. 4c,d and Supplementary Figs. 7a and 8d) . Poly(I:C) also induced DDX3X-IKK-α association (Supplementary Fig. 8d,e) .
In HCV-infected cells, we verified increased interaction of DDX3X with IKK-α using coimmunoprecipitation (Fig. 4f) . Silencing of DDX3X markedly reduced the colocalization of the HCV 3′ UTR with IKK-α, whereas IKK-α siRNA had no effect on complex formation between the HCV 3′ UTR and DDX3X (Supplementary Fig. 7a) , suggesting that interaction of the HCV 3′ UTR with DDX3X is required for the subsequent recruitment and activation of IKK-α. Silencing of MAVS, which has been suggested to interact with DDX3X in the activation of innate immunity 28, 32 , had no effect on interactions among the HCV 3′ UTR, DDX3X and IKK-α (Supplementary Fig. 7a) .
These data indicate that in HCV-infected Huh7.5.1 cells, DDX3X signals predominantly through the IKK-α-mediated lipogenic pathway to play a proviral part in HCV propagation.
Previous studies showed that the HCV core binds and redistributes DDX3X to the viral assembly sites around lipid droplets; however, this interaction seems to be dispensable for HCV replication 33 . In HCVinfected cells, redistributed DDX3X partially colocalized with core and lipid droplets (Supplementary Fig. 8f ). Treatment of Huh7.5.1 cells with the HCV 3′ UTR or poly(I:C) also induced DDX3X-IKK-α association, but the DDX3X-IKK-α complexes did not localize to the lipid droplets ( Fig. 4g and Supplementary Fig. 8e ). To confirm that the core is not involved in the interaction between DDX3X and IKK-α, we studied an HCV mutant with a core amino acid substitution (Y35A) that abolishes its interaction with DDX3X 33 and showed that in the absence of core-DDX3X binding, DDX3X-IKK-α interaction is still induced by HCV infection without lipid droplet association ( Fig. 4h and Supplementary Fig. 8g ).
HCV induces IKK-a phosphorylation and nuclear translocation
We next examined the consequence of DDX3X-IKK-α interaction induced by HCV infection. We infected Huh7.5.1 cells with HCV and harvested them at various time points (4-72 h) after infection to determine IKK-α gene expression. There was no change in either mRNA or protein levels of IKK-α in the presence of HCV infection (Supplementary Fig. 9a,b) . However, we did find a significant increase in phosphorylated IKK-α, representing the active form of IKK-α, at 12-24 h after HCV infection ( Fig. 5a and Supplementary Fig. 9c ). IKK-α, when activated, shuttles from the cytoplasm to the nucleus 15, 16 . We therefore examined the distribution of IKK-α in the nuclear and cytosolic fractions of HCV-infected cells. By 12 h after HCV infection, the cells showed marked nuclear accumulation of IKK-α ( Fig. 5b) . Treatment of cells with tumor necrosis factor-α (TNF-α), a bona fide activator of IKK-α 15 , significantly enhanced the phosphorylation and nuclear translocation of IKK-α, whereas the overall expression of IKK-α remained unchanged (Fig. 5a,b and Supplementary Fig. 9b ). Confocal microscopy confirmed the nuclear accumulation of IKK-α in HCV-infected or HCV 3′ UTR-transfected cells ( Fig. 5c and Supplementary Fig. 9d,e ), and these cells showed a speckle-like association of IKK-α and DDX3X ( Fig. 5c ) and elevated lipid droplet contents ( Supplementary  Fig. 9e,f) , whereas the majority of IKK-α resided in the cytoplasm of uninfected cells. Phosphorylation of IKK-α is required for its nuclear translocation, as the HA-IKK-α KM did not show nuclear localization (Supplementary Fig. 9g ).
IKK-a induces SREBP-mediated lipid droplet formation
We performed microarray gene expression profiling and identified cellular genes that are transcriptionally regulated by IKK-α. We treated Huh7.5.1 cells with either nontargeting control siRNA or IKK-α siRNA in the absence or presence of HCV infection (four conditions total). We confirmed the knockdown efficiency of IKK-α and its effect on HCV infection by measuring IKK-α mRNA and HCV RNA levels ( Supplementary Fig. 10a,b) . Lipogenic genes, particularly SREBPs and SREBP target genes involved in fatty acid and triglyceride synthesis, were upregulated by HCV, and their inductions were abrogated in IKK-α-silenced cells ( Fig. 5d and Supplementary  Fig. 10c-i) . Overexpression of wild-type (WT) IKK-α upregulated, and overexpression of the IKK-α KM downregulated, the expression of SREBPs (Supplementary Fig. 10j ). Under our experimental conditions, the effects of HCV infection and transfection tended to be underestimated, as the efficiencies of infection and transfection were only ~40-50% of cells under the best circumstance. We compared our microarray data set with a recent publication that identified all SREBP-1-regulated lipid metabolism and human hepatic genes 34 . We showed that the genes regulated by SREBP-1 were markedly affected by HCV infection or IKK-α silencing ( Supplementary  Fig. 10k,l) , implying that IKK-α has a major role in SREBP-1 regulation of hepatic lipid metabolism genes. We further demonstrated that npg SREBP knockdown has a similar effect as IKK-α silencing on HCV infection. After depletion of SREBP-1 and SREBP-2, there was a significant impairment of HCV production (Fig. 5e) , likely stemming from the apparent diminution of lipid droplet formation (Fig. 5f) . and Supplementary Fig. 10i ). In PHHs, IKK inhibitors reduced the mRNA levels of SREBP-1 and SREB-2 (Supplementary Fig. 10m ).
IKK-α silencing and IKK inhibitors (wedelolactone and
Silencing of DDX3X, IKK-α, SREBP-1 or SREBP-2 in PHHs led to a substantial reduction of extracellular as compared to intracellular HCV RNA levels ( Supplementary Fig. 11a,b) .
IKK-a induces expression of SREBP through CBP/p300
Activated IKK-α has been shown to phosphorylate CBP and upregulates its activities in the nucleus 18 . CBP/p300 is also involved in SREBP transcriptional activity 35, 36 . Overexpression of CBP/p300 markedly upregulates the expression of both SREBP-1 and SREBP-2 (ref. 37) . We found that both IKK-α and CBP/p300 siRNAs significantly reduced SREBP promoter activities and mRNA levels (Figs. 5d  and 6a and Supplementary Fig. 11c,d) . We also found that IKK-α exerts its effect on SREBP induction and lipogenesis through recruiting the CBP/p300 complex. CBP/p300 depletion by siRNA significantly decreased cytosolic lipid droplet content and HCV production ( Fig. 6b,c) . siRNAs against CBP/p300 markedly diminished HCV 3′ UTR-mediated SREBP-1 induction and lipid droplet formation ( Supplementary Fig. 11d,e ). Using chromatin immunoprecipitation (ChIP) assays, we found that bindings of the SREBP-1 promoter to both IKK-α and CBP were enhanced by HCV infection or HCV 3′ UTR transfection ( Fig. 6d and Supplementary Fig. 11f ). In addition, enhanced viral production by IKK-α overexpression was substantially compromised in cells treated with CBP/p300 or SREBP siRNA (Fig. 6e) , indicating that CBP/p300 and SREBPs are involved in the IKK-α-mediated proviral effect.
To show that the DDX3X-IKK-α-SREBP pathway is indeed crucial for productive HCV infection, we silenced these genes in combination and demonstrated that HCV infection was much more reduced (>100-fold) than when silencing the individual genes ( Supplementary  Fig. 11g ).
DISCUSSION
We demonstrate a previously unrecognized function of IKK-α in regulating cellular lipid metabolism and therefore HCV assembly, both of which are independent of its role in intrinsic innate immunity. We extensively validated and mechanistically investigated this function of IKK-α. We showed that HCV, through the action of the viral 3′ UTR containing a previously identified PAMP, specifically interacts with DDX3X and activates IKK-α to mediate an NF-κBindependent function in the nucleus. Recent accumulating evidence has indicated an emerging role of DDX3X in innate immunity, although the precise mechanism remains unclear 28, 29 . Other members of the DEAD box family, including the well-known RLRs and the recently identified DDX1, DDX21 and DHX36, are important intracellular PRRs for RNA viruses 27 . Although DDX3X has been suggested to function as a PRR 28 , direct evidence for this is lacking. Here we show that DDX3X specifically recognizes the HCV 3′ UTR as a possible PRR. Binding of the HCV 3′ UTR to DDX3X leads to activation of IKK-α. HCV core protein has been shown to bind to DDX3X 33 , but this interaction is dispensable for HCV-triggered activation of the DDX3X-IKK-α pathway.
This pathway involving DDX3X and IKK-α seems to be unique to HCV, as genome-wide siRNA screens of several viruses, including HIV-1, Dengue, West Nile and influenza, using the same screening platform did not identify this pathway as a crucial host factor for these viruses [38] [39] [40] [41] . We therefore propose a model that illustrates the mechanism of action for DDX3X and IKK-α in HCV infection (Fig. 6f) . Unlike other factors in the NF-κB activation pathway that are exclusively antiviral genes, IKK-α, although capable of modestly inducing interferonstimulated gene (ISG) expression ( Supplementary Fig. 12e) , exerts a predominantly proviral effect that targets the assembly stage of the HCV life cycle by activating SREBP-mediated lipogenesis and lipid droplet biogenesis. It is worth noting that various HCV proteins have also been implicated in interacting with host lipid metabolism to facilitate HCV assembly 22, 23 , but our data indicate that the primary trigger of lipid droplet biogenesis is mediated by the viral 3′ UTR, and viral proteins mainly have a downstream role in viral assembly 22, 23 .
RNA viruses selectively exploit host-specific elements to form specialized organelles in which cellular lipids are crucial in enhancing viral production. Dengue virus infection launches an autophagymediated processing of lipid droplets and triglycerides that is required for efficient viral replication 42 . West Nile virus infection stimulates cholesterol biosynthesis and redistributes cholesterol to viral RNA replication membranes 43 . Recently, HCV infection was shown to depend on phosphatidylinositol 4-phosphate (PI4P) lipid-enriched membranes and PI4KIII kinases for RNA replication 44 . HCV infection also induces lipid droplet formation for productive virion assembly 24 . Cellular lipogenesis is coordinated with lipid droplet formation and maturation 45 .
HCV infection is associated with hepatic steatosis and insulin resistance 4 , presumably because of HCV-induced dysregulation of lipid metabolism. Hepatic steatosis contributes substantially to the progression of fibrosis in patients with chronic hepatitis C 46 . Interestingly, hepatic activation of IKK-β and NF-κB has been implicated in the etiology of insulin resistance and type 2 diabetes 47, 48 . Targeted deletion or pharmacological inhibition of IKK-β can restore insulin sensitivity in obese mice and humans 49, 50 . Recent genome-wide association studies have shown that single-nucleotide polymorphisms in the CHUK (encoding IKK-α) gene locus are associated with nonalcoholic fatty liver diseases 51 . As we here functionally link IKK-α to lipogenesis in hepatocytes, it will be interesting to investigate the interaction among the various IKKs in HCV-associated steatosis and insulin resistance, as well as in general cellular metabolism.
IKK-α, as part of the NF-κB activation pathway, is involved in host recognition and defense against pathogen infection. Here we show that IKK-α has an important role in the constitutive maintenance of lipogenic gene expression and lipid droplet formation in hepatocytes, and its activation by HCV further stimulates the lipogenic pathways to facilitate viral assembly. We reason that IKK-α and its associated pathways have a dual effect on HCV infection-an antiviral effect through the NF-κB pathway and a proviral effect through the lipogenic pathway-with the latter being the dominant pathway in our experimental models. IKK-α signaling may therefore be a pivotal mechanism whereby chronic infection and inflammation lead to the dysregulated metabolism that is implicated in the development of various chronic metabolic disorders 52 . Our findings offer crucial insights into the inflammatory origin of metabolic disease and the pathogenic consequences of chronic viral infection 14, 53 .
A comprehensive understanding of the crosstalk between HCV, host innate responses and lipid metabolism may help identify new and broadly active antiviral targets 54 . The discovery of a proviral function of IKK-α offers therapeutic opportunities for IKK-α inhibitors in the treatment of HCV infection. The demonstrated efficacy of commercially available inhibitors of IKK activities in blocking HCV infection in this study provides a proof-of-concept approach for new HCV therapeutic development. We also present the first evidence, to our knowledge, that HCV usurps intrinsic innate immune pathway for its own advantage and survival. Such an exploitation of host antiviral npg defense may underlie the mechanism whereby HCV infection predisposes to persistent infection despite an active host immunity.
METHODS
Methods and any associated references are available in the online version of the paper.
